Kanna Benefits: What the Research Says About Sceletium tortuosum

Most people searching for natural stress relief end up in a frustrating loop. Adaptogens that taste like dirt. Supplements with ingredient lists three paragraphs long. Beverages that promise calm but deliver sedation.

The modern wellness market is full of options that sound good until you try them, and the gap between marketing claims and real-world results has left a lot of people skeptical.

That skepticism is fair. But it does not apply equally to every botanical out there. Sceletium tortuosum, the South African succulent known for thousands of years as kanna, is one of the rare plants with a traceable ethnobotanical history and a growing body of clinical research behind it.

Understanding what the science shows is the first step toward making smarter choices about what you put in your body. This article breaks down what researchers have found, what the plant does at a biochemical level, and why it is showing up in the next generation of functional beverages.

And if you are already convinced that there is a better way to unwind, Kamello is bringing kanna and kava together in a ready-to-drink format built for exactly that. 

Before You Dismiss It as a Trend, Meet Sceletium tortuosum

A Plant That Outlasted Empires: Kanna's Deep Roots

Kanna is not a new discovery. The Khoikhoi and San peoples of southern Africa have used Sceletium tortuosum for centuries, traditionally fermenting the succulent and chewing it to ease hunger, pain, and emotional distress.

Early ethnobotanical records describe its use as a social relaxant and mood stabilizer across the dry, demanding landscapes of Namaqualand and the Karoo. Hunters and farmers reportedly washed aching limbs with it.

That fermentation step is worth pausing on. Traditional preparation deliberately altered the plant's alkaloid profile before consumption. Research published in the journal Molecules confirms that fermentation changes the chemical composition in ways that influence bioavailability and potency, which is likely why traditional users developed the practice in the first place.

This was intuitive pharmacology centuries before the word existed. When a plant has that kind of track record, and ethnobotanists like Dr. Nigel Gericke have spent careers documenting and validating it, the modern wellness interest starts to look less like a trend and more like a rediscovery.

The Tiny Alkaloids Behind Some Very Big Effects

The pharmacological intrigue around this plant comes down to a group of compounds called mesembrine alkaloids. The four most studied are mesembrine, mesembrenone, mesembrenol, and mesembranol.

The plant contains eight closely related alkaloids that work together as an entourage rather than in isolation. Getting the right balance between them is what determines whether a product delivers reproducible, desirable effects, which is why whole-plant or standardized extracts consistently outperform any single isolated compound.

Mesembrine is the most researched of the group. It functions primarily as a serotonin reuptake inhibitor (SRI), blocking the serotonin transporter and increasing serotonin availability in the brain. This is the same core mechanism used by a class of widely prescribed antidepressants, though the plant operates at much lower potency and without the same clinical classification.

The botanical also inhibits an enzyme called phosphodiesterase-4 (PDE4), which plays a role in neuroinflammation. This dual action is what makes Sceletium tortuosum stand out among mood-supporting plants and is central to why researchers keep returning to it.

Why Researchers Are Taking This Seriously

The Brain Scan That Changed the Conversation

Some of the most compelling evidence comes from neuroimaging. To understand why it matters, it helps to know what the amygdala does. It is the brain's threat-detection hub, the region that fires when you perceive danger, social rejection, or uncontrollable pressure.

When it is chronically overactive, the result is persistent anxiety, emotional reactivity, and difficulty feeling at ease even in low-stakes situations.

A randomized, double-blind clinical trial found that a single 25 mg dose of the standardized extract Zembrin produced measurable changes in exactly that region. The fMRI study found reduced reactivity in both the amygdala and the hypothalamus, the two structures at the center of the body's stress response system.

Seeing a botanical compound measurably shift stress-processing circuitry under controlled conditions moves the evidence well beyond self-reported mood surveys. For anyone exploring calming functional beverages, that kind of finding carries real weight.

What Happens When You Give People Kanna and Watch Their Neurons

Beyond neuroimaging, several double-blind, placebo-controlled trials have examined broader effects on mental well-being. A six-week trial found that daily use of Zembrin significantly increased alpha1 and alpha2 brain wave frequencies during cognitive tasks, frequencies associated with calm alertness rather than drowsy sedation.

A separate study found that participants receiving the extract showed significant reductions in anxiety compared to the placebo group.

Perhaps most tellingly, a compound derived from Sceletium tortuosum is currently in an active Phase 1a clinical trial for the treatment of anxiety disorders, with topline results expected in the second half of 2026. Mainstream pharmaceutical research does not invest in Phase 1 trials on a whim. 

That level of institutional attention signals that the botanical is being taken seriously well beyond the wellness industry, lending the conversation a layer of credibility that few adaptogens can claim.

Sharp, Calm, and Focused: The Cognitive Side Nobody Talks About

The PDE4 Factor: Why Kanna Does Not Dull Your Edge

Most botanical relaxants trade sharpness for calm. This one does something different, and the PDE4 mechanism is why.

PDE4 is an enzyme that breaks down cyclic adenosine monophosphate (cAMP), a signaling molecule central to neuroplasticity, learning, and neurotransmission. By inhibiting PDE4, the plant preserves cAMP levels in the brain, supporting the flexible, adaptive neural communication associated with focus and executive function.

A randomized controlled trial involving 60 physically active adults found that 8 days of supplementation at 25 mg per day significantly improved complex reactive performance. A separate study found positive effects on attention and memory.

These findings distinguish kanna from sedating botanicals and position it as a tool for navigating demanding days rather than escaping them.

Can Kanna Help You Sleep? Here Is What the Data Says

Emerging data also points toward an influence on sleep. In the previously mentioned double-blind trial, participants taking Zembrin reported improved subjective sleep quality and a positive effect on sleep onset compared to the placebo group.

This was a secondary finding rather than the primary focus of the study. But it follows logically from the broader mechanism: when amygdala reactivity decreases and the nervous system is no longer running at a heightened state, the physiological conditions for rest naturally improve.

No trials have yet designed sleep quality as a primary outcome measure, and these findings should be understood as early signals rather than established conclusions. Still, the consistency between traditional use reports and modern clinical observations adds a meaningful dimension to what this botanical may offer beyond daytime support.

What You Deserve to Know Before You Try It

Centuries of Use, Clinical Trials, and Still No Red Flags

Across multiple trials using the standardized Zembrin extract at 25 mg daily, researchers found no significant adverse effects on blood pressure, pulse, temperature, or weight. The incidence of treatment-emergent adverse events was low, with no nausea or vomiting reported in controlled settings.

Animal studies have also suggested a favorable toxicology profile.

Ethnobotanical evidence consistently points away from addictive potential, which is a meaningful differentiator in a category where dependency concerns are common. Indigenous communities used the plant in low doses for centuries without documented patterns of dependence, and controlled studies have not surfaced any mechanism that would suggest otherwise.

For anyone cautious about adding a new ingredient to their routine, that combination of historical and clinical evidence is genuinely reassuring. It is also part of why Kamello built transparency into its brand identity from day one.

Where the Science Is Honest About Its Own Limits

Responsible coverage requires acknowledging what remains unproven. A meta-analysis of four randomized trials involving 117 adults found no statistically significant difference in pooled anxiety outcomes between the extract and placebo groups.

Most individual studies have been small, short in duration, and conducted exclusively with healthy adults rather than clinical populations. Regulatory bodies note that data are not yet sufficient to support the plant for any specific medical indication.

None of that makes it less worth understanding. It means the research is still catching up to a long tradition of observed use. The mechanistic data, the neuroimaging results, and the cognitive performance findings all point in a consistent direction, and the presence of active pharmaceutical trials signals that serious investment is following.

Kamello engages with this botanical on those honest terms rather than overclaiming effects the science has not yet fully quantified.

Ancient Botanical, Modern Can: How Kanna Is Entering Everyday Life

Two Botanicals, One Formula: The Logic Behind Pairing Kava and Kanna

One of the things that sets Kamello apart is the decision to combine both kava and kanna in a single ready-to-drink format.  Kava (Piper methysticum) is a Pacific Island plant studied for its ability to promote physical relaxation through kavalactones that interact with GABA receptors. 

The addition of kanna brings the serotonergic and cognitive clarity component, addressing the emotional and mental dimensions of stress that kava does not directly target.

The pairing also speaks directly to the sober curious movement. A growing number of people are actively reducing or replacing alcohol and looking for alternatives that support social ease without impairment or next-day consequences.

Kava provides the physical unwinding that alcohol mimics and kanna provides the mood lift. Together they cover the full experience without the hangover, which is precisely the gap Kamello was built to fill.

Why Drinking Your Botanicals Changes Everything

Sceletium tortuosum has historically arrived in capsules, tablets, or tinctures. Translating it into a canned beverage is a meaningful formulation challenge.

Clinical trials have used 25 mg of standardized Zembrin as the benchmark dose, and standardization of alkaloid content is what separates products that perform reliably from those that do not. Format and standardization are not minor details when effects depend on the precise balance of eight active compounds.

Beyond formulation, the beverage format changes the context of use entirely. A capsule is consumed privately as part of a supplement routine. A canned drink is social, shareable, and woven into the moments people are already navigating: the post-work wind-down, the weekend gathering, the event where everyone else is drinking.

That is the context this plant's traditional use was always rooted in, and it is the context Kamello is designed for.

Your New Ritual Is Closer Than You Think

The case for kanna is not built on marketing. It is built on centuries of traditional use, a growing body of clinical research, and well-understood biochemical mechanisms.

The plant inhibits serotonin reuptake, reduces amygdala reactivity, and preserves cognitive sharpness through PDE4 inhibition, all without the dependency concerns associated with pharmaceutical alternatives. Two of its compounds are already in Phase 1 trials, a sign that mainstream science is paying close attention.

What the research makes clear is that this is not a magic fix. It is a pharmacologically active botanical that supports mood resilience and mental calm when used thoughtfully.

Paired with kava in Kamello's formulation, it becomes part of a broader system for navigating modern life without leaning on alcohol or sedatives. If you have been curious about ethnobotanicals but wanted to see the evidence first, explore Kamello's full line today and decide for yourself whether ancient botanicals belong in your modern routine.

Frequently Asked Questions

Is kanna the same as kratom?

No. Kanna and kratom are completely different plants, and the distinction matters for both safety and expectations. 

Kanna comes from Sceletium tortuosum, a South African succulent traditionally used for mood, stress, and social ease. Modern research on standardized kanna extracts focuses mainly on mesembrine-type alkaloids that appear to influence serotonin transport and PDE4 activity, as shown in human research on Zembrin.

Kratom comes from Mitragyna speciosa, a Southeast Asian tree with a very different alkaloid profile. Kratom’s best-known alkaloids, mitragynine and 7-hydroxymitragynine, are discussed differently from kanna because they can interact with opioid-related pathways.

The FDA’s kratom overview notes that kratom has been associated with serious adverse events, including liver toxicity, seizures, substance use disorder, and rare deaths in reports that often involved other substances.

This means kanna and kratom should not be grouped together simply because they are both botanicals. Kanna is usually discussed in relation to stress response, mood, and cognition, while kratom raises separate opioid-receptor, dependency, and contamination concerns. Someone looking for a calming botanical should not assume that one can be swapped for the other.

The clearest way to compare them is by mechanism, evidence, product quality, and personal risk factors. Kanna is not risk-free, especially for people using serotonergic medications, but it is not pharmacologically equivalent to kratom. Treating them as interchangeable can lead to poor safety decisions and unrealistic expectations about how each plant may feel.

Does the way kanna is consumed affect how well it works?

Yes. The way kanna is prepared and consumed can influence how consistent, predictable, and noticeable its effects are. Traditional kanna use included chewing and fermented preparations, while modern products may appear as capsules, tinctures, powders, gummies, teas, or ready-to-drink beverages.

The most important point is that the strongest human research does not apply equally to every product format. Many clinical studies have used standardized extracts, not generic kanna powder or unverified blends. A standardized extract is designed to deliver a more consistent chemical profile, which matters because kanna’s effects are tied to mesembrine-type alkaloids.

For example, a randomized, double-blind, placebo-controlled safety study tested standardized Zembrin at 8 mg and 25 mg daily in healthy adults, and both doses were reported as well tolerated over 3 months in the published safety trial. That is useful evidence, but it does not automatically prove that every kanna drink, capsule, tincture, or gummy will behave the same way.

This is why label transparency matters. A higher-quality kanna product should identify the plant clearly as Sceletium tortuosum, disclose the extract or preparation type, list the amount per serving, and avoid vague claims like “strong mood boost” without explaining what is actually in the product. Products that do not disclose dose or extract details are harder to evaluate.

Food intake, serving size, individual sensitivity, and combination formulas can also affect the experience. A kanna beverage that includes other functional ingredients may feel different from a single-ingredient capsule because the overall formulation changes the context. 

For most people, the practical question is not only “how is it consumed?” but also “is the product standardized, transparent, and responsibly formulated?”

Does kanna interact with prescription antidepressants?

Kanna may interact with prescription antidepressants or other serotonergic medications, so this question deserves caution. 

Research on standardized Sceletium tortuosum extracts suggests activity related to serotonin transport, and human fMRI research describes Zembrin as having dual 5-HT reuptake inhibition and PDE4 inhibition activity in the context of anxiety-related brain circuitry, as shown in the Zembrin study.

The main concern is serotonin overload. Serotonin syndrome, also called serotonin toxicity, can happen when too much serotonergic activity affects the nervous system. 

A clinical review in British Journal of Clinical Pharmacology describes serotonin syndrome as a potentially life-threatening toxidrome associated with increased serotonergic activity and symptoms involving mental status, autonomic function, and neuromuscular activity, as explained in this review of serotonin toxicity.

For kanna, the risk is best described as mechanistic and precautionary rather than fully quantified in human interaction trials. There is not enough direct clinical research showing exactly what happens when kanna is combined with SSRIs, SNRIs, MAOIs, tricyclic antidepressants, migraine medications, stimulants, mood stabilizers, or other serotonin-active products. That uncertainty is exactly why caution is appropriate.

Anyone taking prescription antidepressants, anti-anxiety medications, mood stabilizers, antipsychotics, migraine drugs, or other psychiatric medications should talk with a healthcare professional before using kanna. This is especially important because supplements can still have biologically active effects even when they are sold outside the prescription-drug system.

Are there any populations who should avoid kanna entirely?

Some people should avoid kanna or use it only with medical guidance. This includes anyone taking serotonergic medications, anyone with a complex psychiatric medication regimen, and anyone with a history of serotonin syndrome or serious medication interactions. 

FDA consumer guidance on dietary supplements notes that supplements can interact with medicines, affect the body in active ways, and should be discussed with a healthcare professional when safety questions exist.

People with bipolar disorder or a history of mania should be especially cautious. This is not because kanna has been proven to trigger mania in clinical trials. The issue is that kanna appears to affect serotonin-related pathways, and serotonin-influencing substances require extra care in people who are vulnerable to mood cycling.

A review in NCBI Bookshelf found that antidepressant treatment in adults with bipolar or major depressive disorder was associated with a moderately increased risk of mania or hypomania overall, as summarized in the review on antidepressant-associated mania. Kanna is not the same as a prescription antidepressant, but the precaution is reasonable because of its serotonin-related activity.

Pregnant and breastfeeding individuals should also avoid kanna unless a qualified healthcare professional specifically advises otherwise. The concern is limited human safety data, not proven harm. Most kanna studies have been conducted in healthy adults, so safety cannot be assumed for pregnancy, breastfeeding, infants, or developing children.

Children and adolescents should not use kanna without medical supervision. The available human evidence is not built around pediatric use, and developing nervous systems may respond differently to psychoactive or mood-active ingredients. 

People with liver disease, serious heart conditions, seizure disorders, or multiple medications should also be cautious because product-specific safety data is limited.

The safest approach is to treat kanna as a pharmacologically active botanical, not as a casual flavor ingredient. For healthy adults, studied standardized extracts have generally looked well tolerated in small trials, but that does not remove the need for caution in higher-risk groups.

Is kanna legal?

Kanna’s legal status is more complicated than a simple yes or no. 

In the United States, kanna is not commonly treated like a federally scheduled controlled substance in the same way as substances listed under the Controlled Substances Act. The DEA explains that the Controlled Substances Act organizes regulated drugs into schedules based on medical use, abuse potential, and safety or dependence liability, as outlined in its CSA overview.

However, not being treated as a scheduled controlled substance does not mean every kanna product is automatically approved, risk-free, or legal in every format. A product can raise regulatory concerns based on how it is marketed, what claims it makes, how it is manufactured, and whether it is sold as a food, dietary supplement, beverage ingredient, or drug-like product.

In the U.S., dietary supplements are regulated differently from prescription and over-the-counter drugs. FDA’s dietary supplement guidance explains that supplements are not evaluated like drugs for safety and effectiveness before they reach the market. This is why legality should not be confused with clinical approval.

There may also be ingredient-specific questions. FDA explains that a “new dietary ingredient” generally means a dietary ingredient that was not marketed in the United States in a dietary supplement before October 15, 1994, and such ingredients may require notification depending on the facts, according to the agency’s NDI overview.

Outside the U.S., kanna’s status may vary by country, product category, and intended use. Some jurisdictions may treat botanicals differently depending on whether they are sold as foods, supplements, medicines, or psychoactive products. For that reason, consumers and brands should check current local rules rather than assuming a kanna product is regulated the same way everywhere.

Can kanna cause side effects?

Yes. Kanna can cause side effects, even though the best-studied standardized extracts have generally been well tolerated in small human trials. “Natural” does not mean inactive, and kanna’s potential benefits are connected to the same pharmacological activity that makes safety context important.

In one randomized, double-blind, placebo-controlled study, healthy adults took 8 mg or 25 mg of standardized Zembrin daily for 3 months, and both doses were reported as well tolerated in the published safety trial. The study did not show major safety signals in that population, which is encouraging for standardized extract research.

Still, the findings have limits. The trial involved healthy adults, a specific standardized extract, and defined daily doses. It does not prove that every kanna product, higher-dose product, multi-ingredient formula, or long-term use pattern will have the same safety profile. It also does not answer every question about use in people with medical conditions or medication regimens.

Possible side effects may include headache, nausea, digestive discomfort, sleep changes, jitteriness, drowsiness, or changes in mood, although the exact pattern may depend on dose, product type, and individual sensitivity. 

Because kanna may influence serotonin-related pathways, symptoms such as agitation, confusion, tremor, sweating, rapid heartbeat, or unusual mood changes should be taken seriously, especially if other serotonergic substances are involved.

People should be especially careful when combining kanna with alcohol, sedatives, antidepressants, stimulants, cannabis, or other botanicals that affect mood, sleep, or alertness. Combination use can make effects less predictable and may increase the chance of unwanted reactions.

A cautious approach is to start with a clearly labeled product, avoid stacking it with other psychoactive substances, and avoid driving or operating machinery until you know how your body responds. If side effects feel intense, unusual, or persistent, stop using the product and seek medical guidance.